Computational and Structural Biotechnology Journal (Jan 2023)

HDAC2 as a target for developing anti-cancer drugs

  • Hyein Jo,
  • Kyeonghee Shim,
  • Han-Ul Kim,
  • Hyun Suk Jung,
  • Dooil Jeoung

Journal volume & issue
Vol. 21
pp. 2048 – 2057

Abstract

Read online

Histone deacetylases (HDACs) deacetylate histones H3 and H4. An imbalance between histone acetylation and deacetylation can lead to various diseases. HDAC2 is present in the nucleus. It plays a critical role in modifying chromatin structures and regulates the expression of various genes by functioning as a transcriptional regulator. The roles of HDAC2 in tumorigenesis and anti-cancer drug resistance are discussed in this review. Several reports suggested that HDAC2 is a prognostic marker of various cancers. The roles of microRNAs (miRNAs) that directly regulate the expression of HDAC2 in tumorigenesis are also discussed in this review. This review also presents HDAC2 as a valuable target for developing anti-cancer drugs.

Keywords